VRE; a public health context

This report published in Communicable Diseases Intelligence Volume 22, No 11, 29 October 1998 contains an editorial on vancomycin-resistant enterococci.

Page last updated: 04 November 1998

A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.

Alexandra Geue, Senior Microbiologist, National Centre for Disease Control

In recent weeks newspapers around Australia have reported outbreaks of vancomycin-resistant enterococci (VRE) in five Victorian hospitals. To date, VRE has not been a major cause of hospital infection in Australia, unlike the United States where it has become a major nosocomial pathogen. Since 1994, when Australia's first case of VRE was detected, the National Antimicrobial Resistance Surveillance Program (NARSP) has collected data on 69 cases of VRE from around Australia which are presented in a timely report for this issue of CDI.1

The outbreaks in Victoria serve as a reminder that we must constantly examine and improve our public health practices. Vancomycin is currently the last line of treatment against methicillin resistant Staphylococcus aureus, a common cause of nosocomial infection in Australia. Japan and the United States have already seen nosocomial infections with S. aureus that have resistance to vancomycin. Australia needs to heed this warning and re-examine current practice. Community use of antibiotics in Australia is one of the highest in the developed world.2 Antibiotics are also used in animal feeds. The extent to which these practices are contributing to the increasing antibiotic resistant pathogens in humans is largely unknown, but this question is being examined by the Joint Expert Technical Advisory Committee on Antimicrobial Resistance (JETACAR), a joint initiative of the Federal Ministers for Health and Industries. This committee is expected to complete its work before 1999.

Effective infection control in health care settings remains a vital strategy in containing and preventing nosocomial infections. In the National Centre for Disease Control a review of the national infection control guidelines Infection Control in the Health Care Setting is under way. This will utilise experts from across the health care professions in drafting a new national infection control policy. The revised document will include more comprehensive and up-to-date information for controlling antibiotic resistant organisms in health care settings.

Last but not least, outbreaks of VRE remind us of the importance of surveillance. Early detection of resistant organisms can provide important early warnings of changes in our environment that may impact on public health. Without comprehensive active surveillance we can not develop effective or well targeted infection control policies. Surveillance of nosocomial infections and antibiotic resistance in animals and humans has been identified as a high public health priority by the Communicable Disease Network Australia New Zealand.


1. Bell J, Turnidge J, Coombs G, O'Brien F. Emergence and epidemiology of vancomycin-resistant enterococci in Australia. Commun Dis Intell 1998;22:249-252.

2. McManus P, Hammond ML, Whicker SD, Primrose JG, Mant A, and Fairall SR. Antibiotic use in the Australian community, 1990-1995. MJA 1997;167:124-127.

This article was published in Communicable Diseases Intelligence Volume 22, No 11, 29 October 1998.

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now

This issue - Vol 22, No 11, 29 October 1998